CONSOLIDATED STATEMENT OF CASH FLOWS (USD $)	6 Months Ended		86 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014
CASH FLOW FROM OPERATING ACTIVITIES
Net loss	$ (1,773,654)	$ (1,083,246)	$ (17,170,951)
Adjustments to reconcile net loss to net cash used in operating activities
Amortization	80,312	80,312	1,217,670
Technology impairment	0	0	690,000
Common stock issued for services	0	0	318,500
Stock options and warrants	209,071	29,557	3,927,304
(Increase) decrease in assets
Prepaid drug product for testing	(89,981)	(84,180)	(141,345)
Other current assets	(107,446)	(3,836)	(171,563)
Increase (decrease) in liabilities
Accounts payable and accrued expenses	38,621	(61,388)	333,519
Net cash used in operating activities	(1,643,077)	(1,122,781)	(10,996,866)
CASH FLOW FROM INVESTING ACTIVITIES
Purchase of exclusive license - related party	0	0	(884,710)
Net cash used in investing activities	0	0	(884,710)
CASH FLOW FROM FINANCING ACTIVITIES
Proceeds from convertible notes	0	0	435,000
Cash repayment of convertible notes	0	0	(15,000)
Net proceeds from sale of common stock	13,812,373	2,515,961	27,182,704
Net cash from financing activities	13,812,373	2,515,961	27,602,704
NET INCREASE (DECREASE) IN CASH	12,169,296	1,393,180	15,721,128
Cash, beginning of period	3,551,832	534,046	0
Cash, end of period	15,721,128	1,927,226	15,721,128
Cash paid for
Interest	0	0	445
Income taxes	0	0	0
Non-cash financing activities
Common stock issued upon conversion of convertible notes	0	0	420,000
Placement Agent
Non-cash financing activities
Common stock issued	0	448,950	1,362,613
MD Anderson for License
Non-cash financing activities
Common stock issued	0	0	2,354,167
LPC
Non-cash financing activities
Common stock issued	$ 0	$ 0	$ 210,755